The agency said the main concern with the excluded safety update is it “could lead to life-threatening adverse events; although, based on a Health Hazard Assessment conducted by Teva, the likelihood of the harm occurrence is considered remote.”
The opiates are sold under Teva’s Mayne Pharma label, and no complaints have been reported concerning the labeling.
